Skip to main content
SpringerLink
Log in

Risk of serious infections increases with tofacitinib versus bDMARDs

  • Clinical study
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Reference

  • Serious infection risk of tofacitinib compared to biologics in patients with rheumatoid arthritis treated in routine clinical care Scientific Reports : 18 Oct 2023. Available from: URL: https://doi.org/10.1038/s41598-023-44841-w

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Risk of serious infections increases with tofacitinib versus bDMARDs. Reactions Weekly 1980, 12 (2023). https://doi.org/10.1007/s40278-023-48204-7

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40278-023-48204-7

Search

Navigation